Showing results (151-160 of 194) with videos related to
Sort By:
Pageof 20
Nature Communications|August 29, 2024
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phasesLindsey R Baden, Hana M El Sahly, Brandon Essink, et al.Nature Communications|June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administrationDean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.Open Forum Infectious Diseases|March 10, 2023
Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy TrialDean Follmann, Holly E Janes, Eric Chu, et al.Science (New York, N.Y.)|July 10, 2010
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1Xueling Wu, Zhi-Yong Yang, Yuxing Li, et al.Science (New York, N.Y.)|May 11, 2013
Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralizationIvelin S Georgiev, Nicole A Doria-Rose, Tongqing Zhou, et al.NPJ Vaccines|January 17, 2026
Association between COVID-19 vaccine efficacy and epidemic force of infectionJing Xu, M Elizabeth Halloran, Mia Moore, et al.JAMA Network Open|January 23, 2023
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine TrialsAlfredo J Mena Lora, Jessica E Long, Yunda Huang, et al.The New England Journal of Medicine|October 19, 2012
Linezolid for treatment of chronic extensively drug-resistant tuberculosisMyungsun Lee, Jongseok Lee, Matthew W Carroll, et al.Nature|July 22, 2014
Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progressionNetanya G Sandler, Steven E Bosinger, Jacob D Estes, et al.Lancet (London, England)|January 29, 2019
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 studyMartin R Gaudinski, Emily E Coates, Laura Novik, et al.Pageof 20